BMYBristol Myers Squibb
Price
+34%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, undemanding price, growing in the filings, the market undecided.
We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Bristol Myers Squibb (BMY) reported revenue of $13.0B in Q2 2026 (quarter ended Jun 30, 2026), up 5.7% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $3.32B (26% of revenue). For the full year FY2025, revenue was $48.2B (−0.2% year on year) and net income $7.05B. Its largest product in Q2 2026 was Eliquis at $4.48B, 33% of the disclosed total, ahead of Opdivo at 18%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook.Earnings release · press release
- Apr 30, 2026Bristol Myers Squibb Reports First Quarter Financial Results for 2026.Earnings release · press release
- Feb 5, 2026Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $13.75BThe company’s own SEC segment disclosure.
- Eliquis$4.48B33%
- Opdivo$2.48B18%
- Orencia$1.03B8%
- Yervoy$769.0M6%
- Reblozyl$735.0M5%
- Other Growth Brands$653.0M5%
- Other (16)$3.60B26%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry